FDA
-
-
-
-
-
-
-
Incannex gets U.S. patent for sleep apnea drug IHL-42X through 2040
-
-
-
-
-
-
-
Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development
-
-
-
-
-
-
-
Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA)
-
-
-
-
-
-
-
Incannex reports positive Phase 2 results for sleep apnea drug candidate
-
-
-
-
-
-
-
Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates
-
-
-
-
-
-
-
Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates
-
-
-
-
-
-
-
Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X
-
330,741 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

